OACCW Company Profile and Key Details

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACCW) closed at $0.89 USD, losing -$0.06 (-6.32%) from the previous close of $0.95. The stock is currently within 5% of its 52-week low $0.88 and $0.99. With a market capitalization of about $249.98 million, Oaktree Acquisition Corp. III Life Sciences is classified as a micro-cap and shows lower-than-market volatility (beta ~0.20). Key stats such as the average daily volume over the past year has been around 2.81 thousand shares, trading with heavier-than-usual volume. Headquartered in Los Angeles, CA, Oaktree Acquisition Corp. III Life Sciences operates in the Financial Services sector and the Shell Companies industry. Led by CEO Zaid Pardesi, the company employs approximately 1,500 people and listed since October 06, 2025. Oaktree Acquisition Corp. III Life Sciences presently lacks significant commercial operations.

Average 10-day trading volume of 41.16 thousand shares is significantly above the 3-month average of 6.42 thousand, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Valuation shows Oaktree Acquisition Corp. III Life Sciences trading at a premium to the broader market with a P/E of 38.26.

Our AI price prediction model suggests that Oaktree Acquisition Corp. III Life Sciences stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Oaktree Acquisition Corp. III Life Sciences trades at a P/E ratio of 38.26, slightly above the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.05 suggesting the stock is closer to book value. The P/FCF stands at -583.7, also below market averages.